Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

4-Antibody AG

Division of Agenus Inc.
www.4-antibody.com

Latest From 4-Antibody AG

FINANCE ROUNDUP: Six VC financings and a royalty deal

Biotechnology companies and their investors came back from summer break with a slew of venture capital funding rounds and a royalty deal, although it remains to be seen how many early-stage firms will remain financially independent with large biotech and pharmaceutical companies raising massive stockpiles of cash.

Metabolic Disorders Immune Disorders

Agenus dives deeper into checkpoint inhibitors

Cancer Italy

Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making

Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.

BioPharmaceutical Deals

BioNotebook: Incyte, Agenus sign $410m immuno-oncology pact; plus six more deals

Incyte will pay Agenus $60m up front and $350m in development, regulatory and commercial milestone fees to license the Retrocyte Display antibody discovery platform for the development of novel immunotherapies. The upfront fee is comprised of a $25m technology and program access fee as well as a $35m equity investment at $4.51 per share.

Cancer Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Agenus Inc.
  • Senior Management
  • Robert F Burns, PhD, CEO
    Luis Martin-Parras, PhD, Head, R&D & Admin.
    Andreas Richter, Fin. Consultant
  • Contact Info
  • 4-Antibody AG
    Phone: (41) 61 633 22 60
    Hochbergerstrasse 60C
    Basel, CH-4057
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register